Trials / Completed
CompletedNCT04099732
A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the relative bioavailability of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1358894 (Test 1, Test 2) following oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | Tablet |
| DRUG | BI 1358894 | Tablet |
| DEVICE | Dabigatran etexilate | Capsule |
Timeline
- Start date
- 2019-10-07
- Primary completion
- 2019-12-10
- Completion
- 2019-12-10
- First posted
- 2019-09-23
- Last updated
- 2025-02-27
- Results posted
- 2025-02-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04099732. Inclusion in this directory is not an endorsement.